Targeting Natural Killer Cells in Cancer Immunotherapy

Overview

Journal Nat Immunol

Date 2016 Aug 20

PMID 27540992

Citations 581

Authors

Camille Guillerey

Nicholas D Huntington

Mark J Smyth

Affiliations

Soon will be listed here.

Abstract

Alteration in the expression of cell-surface proteins is a common consequence of malignant transformation. Natural killer (NK) cells use an array of germline-encoded activating and inhibitory receptors that scan for altered protein-expression patterns, but tumor evasion of detection by the immune system is now recognized as one of the hallmarks of cancer. NK cells display rapid and potent immunity to metastasis or hematological cancers, and major efforts are now being undertaken to fully exploit NK cell anti-tumor properties in the clinic. Diverse approaches encompass the development of large-scale NK cell-expansion protocols for adoptive transfer, the establishment of a microenvironment favorable to NK cell activity, the redirection of NK cell activity against tumor cells and the release of inhibitory signals that limit NK cell function. In this Review we detail recent advances in NK cell-based immunotherapies and discuss the advantages and limitations of these strategies.

Citing Articles

A chimeric antigen receptor tailored to integrate complementary activation signals potentiates the antitumor activity of NK cells.

Yi E, Lee E, Park H, Lee H, Yun S, Kim H J Exp Clin Cancer Res. 2025; 44(1):86.

PMID: 40045373 PMC: 11884141. DOI: 10.1186/s13046-025-03351-5.

Frizzled-7-targeting antibody-derived bifunctional protein retargets NK cells against triple-negative breast cancer cells via MICA-NKG2D axis.

Wang C, Wu L, Li X, Mao S, Wang Z, Xie H J Immunother Cancer. 2025; 13(2).

PMID: 40021214 PMC: 11873350. DOI: 10.1136/jitc-2024-009621.

Allogeneic CD33-directed CAR-NKT cells for the treatment of bone marrow-resident myeloid malignancies.

Li Y, Fang Y, Niu S, Zhu Y, Chen Y, Lyu Z Nat Commun. 2025; 16(1):1248.

PMID: 39893165 PMC: 11787387. DOI: 10.1038/s41467-025-56270-6.

Research Progress of NK Cells in Glioblastoma Treatment.

Wu H, Liu Q, Wang F, Gao W, Zhou F, Zhao H Onco Targets Ther. 2025; 18():87-106.

PMID: 39845286 PMC: 11752833. DOI: 10.2147/OTT.S486411.

Metabolic interplays between the tumour and the host shape the tumour macroenvironment.

Altea-Manzano P, Decker-Farrell A, Janowitz T, Erez A Nat Rev Cancer. 2025; .

PMID: 39833533 DOI: 10.1038/s41568-024-00786-4.

References

Gerdes C, Nicolini V, Herter S, van Puijenbroek E, Lang S, Roemmele M . GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab. Clin Cancer Res. 2012; 19(5):1126-38. DOI: 10.1158/1078-0432.CCR-12-0989. View

Genssler S, Burger M, Zhang C, Oelsner S, Mildenberger I, Wagner M . Dual targeting of glioblastoma with chimeric antigen receptor-engineered natural killer cells overcomes heterogeneity of target antigen expression and enhances antitumor activity and survival. Oncoimmunology. 2016; 5(4):e1119354. PMC: 4839317. DOI: 10.1080/2162402X.2015.1119354. View

Borg C, Terme M, Taieb J, Menard C, Flament C, Robert C . Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. J Clin Invest. 2004; 114(3):379-88. PMC: 489961. DOI: 10.1172/JCI21102. View

Pogge von Strandmann E, Hansen H, Reiners K, Schnell R, Borchmann P, Merkert S . A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivo. Blood. 2005; 107(5):1955-62. DOI: 10.1182/blood-2005-05-2177. View

Mocellin S, Panelli M, Wang E, Rossi C, Pilati P, Nitti D . IL-10 stimulatory effects on human NK cells explored by gene profile analysis. Genes Immun. 2004; 5(8):621-30. DOI: 10.1038/sj.gene.6364135. View

Wu L, Adams M, Carter T, Chen R, Muller G, Stirling D . lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Clin Cancer Res. 2008; 14(14):4650-7. DOI: 10.1158/1078-0432.CCR-07-4405. View

Klingemann H . Challenges of cancer therapy with natural killer cells. Cytotherapy. 2014; 17(3):245-9. DOI: 10.1016/j.jcyt.2014.09.007. View

Boltz A, Piater B, Toleikis L, Guenther R, Kolmar H, Hock B . Bi-specific aptamers mediating tumor cell lysis. J Biol Chem. 2011; 286(24):21896-905. PMC: 3122244. DOI: 10.1074/jbc.M111.238261. View

Jones B, Lamb L, Goldman F, Di Stasi A . Improving the safety of cell therapy products by suicide gene transfer. Front Pharmacol. 2014; 5:254. PMC: 4245885. DOI: 10.3389/fphar.2014.00254. View

10.

Romee R, Leong J, Fehniger T . Utilizing cytokines to function-enable human NK cells for the immunotherapy of cancer. Scientifica (Cairo). 2014; 2014:205796. PMC: 4099226. DOI: 10.1155/2014/205796. View

11.

Zamora A, Grossenbacher S, Aguilar E, Murphy W . Models to Study NK Cell Biology and Possible Clinical Application. Curr Protoc Immunol. 2015; 110:14.37.1-14.37.14. PMC: 4772895. DOI: 10.1002/0471142735.im1437s110. View

12.

Paolino M, Choidas A, Wallner S, Pranjic B, Uribesalgo I, Loeser S . The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells. Nature. 2014; 507(7493):508-12. PMC: 6258903. DOI: 10.1038/nature12998. View

13.

Nowak J, Koscinska K, Mika-Witkowska R, Rogatko-Koros M, Mizia S, Jaskula E . Role of Donor Activating KIR-HLA Ligand-Mediated NK Cell Education Status in Control of Malignancy in Hematopoietic Cell Transplant Recipients. Biol Blood Marrow Transplant. 2015; 21(5):829-39. DOI: 10.1016/j.bbmt.2015.01.018. View

14.

Rueff J, Medinger M, Heim D, Passweg J, Stern M . Lymphocyte subset recovery and outcome after autologous hematopoietic stem cell transplantation for plasma cell myeloma. Biol Blood Marrow Transplant. 2014; 20(6):896-9. DOI: 10.1016/j.bbmt.2014.03.007. View

15.

Glienke W, Esser R, Priesner C, Suerth J, Schambach A, Wels W . Advantages and applications of CAR-expressing natural killer cells. Front Pharmacol. 2015; 6:21. PMC: 4325659. DOI: 10.3389/fphar.2015.00021. View

16.

Gleason M, Verneris M, Todhunter D, Zhang B, McCullar V, Zhou S . Bispecific and trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine production. Mol Cancer Ther. 2012; 11(12):2674-84. PMC: 3519950. DOI: 10.1158/1535-7163.MCT-12-0692. View

17.

Kellner C, Hallack D, Glorius P, Staudinger M, Mohseni Nodehi S, de Weers M . Fusion proteins between ligands for NKG2D and CD20-directed single-chain variable fragments sensitize lymphoma cells for natural killer cell-mediated lysis and enhance antibody-dependent cellular cytotoxicity. Leukemia. 2011; 26(4):830-4. DOI: 10.1038/leu.2011.288. View

18.

Xu L, Huang Y, Tan L, Yu W, Chen D, Lu C . Increased Tim-3 expression in peripheral NK cells predicts a poorer prognosis and Tim-3 blockade improves NK cell-mediated cytotoxicity in human lung adenocarcinoma. Int Immunopharmacol. 2015; 29(2):635-641. DOI: 10.1016/j.intimp.2015.09.017. View

19.

Pires da Silva I, Gallois A, Jimenez-Baranda S, Khan S, Anderson A, Kuchroo V . Reversal of NK-cell exhaustion in advanced melanoma by Tim-3 blockade. Cancer Immunol Res. 2014; 2(5):410-22. PMC: 4046278. DOI: 10.1158/2326-6066.CIR-13-0171. View

20.

Huntington N, Vosshenrich C, Di Santo J . Developmental pathways that generate natural-killer-cell diversity in mice and humans. Nat Rev Immunol. 2007; 7(9):703-14. DOI: 10.1038/nri2154. View